Home › Companies › ARTV

Pipeline (6 active programs)

Discontinued (8)

• AlloNK — Rheumatoid Arthritis · insufficient durability of clinical response and safety events (Grade 5)
• AlloNK — Sjögren's Disease · insufficient durability of clinical response and safety events (Grade 5)
• AlloNK — Systemic Sclerosis · insufficient durability of clinical response and safety events (Grade 5)
• AlloNK — Idiopathic Inflammatory Myopathies · insufficient durability of clinical response and safety events (Grade 5)
• AlloNK — Systemic Lupus Erythematosus · insufficient durability of clinical response and safety events (Grade 5)
• AlloNK — Lupus Nephritis · insufficient durability of clinical response and safety events (Grade 5)
• AlloNK — Pemphigus Vulgaris · insufficient durability of clinical response and safety events (Grade 5)
• AlloNK — ANCA-Associated Vasculitis · insufficient durability of clinical response and safety events (Grade 5)

Capital (as filed)

Cash

$301M cash and cash equivalents · Jun 30, 2026 (10-Q)

Short-term investments

$47.9M Jun 30, 2026

Operating cash flow

−$20.4M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)

As stated in coverage

$319M cash per the update of Oct 27, 2026 — the company's own words as read there, not the filed figure

Offering documents (3)

• 2026-08-06 S-3 · Shelf registration up to $400M aggregate
• 2026-05-08 424B5 · Priced offering 23.9M shares · at $11.52 · $300M gross · 8.0% below the prior close ($12.52, May 7, 2026) · incl. pre-funded warrants
• 2026-05-08 FWP · Pricing term sheet

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (10)

• 2026-10-28 UPDATE: Artiva (ARTV) - Both Halves of the Bet Broke 🔒 Paid
• 2026-08-07 UPDATE: Artiva (ARTV) - The CFO Clock Ran Out. Nobody Blinked. 🔒 Paid
• 2026-07-24 UPDATE: Artiva (ARTV) - Kolchinsky Keeps Buying. Now at 37.9%. 🔒 Paid
• 2026-06-16 UPDATE: Artiva (ARTV) - RA Capital Goes to 36.6%
• 2026-06-08 UPDATE: Artiva (ARTV) - RMAT Lands, EULAR Confirms, CFO Seat Still Empty
• 2026-05-19 UPDATE: Artiva (ARTV) - The CFO Walks. Ten Days After the Raise. 🔒 Paid
• 2026-05-09 UPDATE: Artiva (ARTV) - The Watch List Pays Off 🔒 Paid
• 2026-03-14 UPDATE: Artiva (ARTV) - The Autoimmune Pivot is Complete... 🔒 Paid
• 2026-02-28 UPDATE: Artiva (ARTV) - The CFO Red Flag is Gone... 🔒 Paid
• 2025-12-17 Artiva Biotherapeutics (ARTV): Scientific Due Diligence for AlloNK and Pipeline Products

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (10 calls)

Every verdict Biotech Distilled has published on Artiva Biotherapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

1. 2025-12-17 Watch Artiva Biotherapeutics (ARTV): Scientific Due Diligence for AlloNK and Pipeline Products Science may be sound but CFO departure, dilution risk, and unproven durability warrant waiting for 6-month RA data before committing capital.
2. 2026-02-28 Watch UPDATE: Artiva (ARTV) - The CFO Red Flag is Gone... New CFO hire with Kite/J&J pedigree and ex-AbbVie board addition strengthen M&A thesis, but Watch List maintained pending data.
3. 2026-03-14 Watch UPDATE: Artiva (ARTV) - The Autoimmune Pivot is Complete... Pure-play autoimmune pivot confirmed and M&A team stacking validated, but binary 1H 2026 data readout still pending; Watch List maintained.
4. 2026-05-09 Speculative buy speculative UPDATE: Artiva (ARTV) - The Watch List Pays Off 71% ACR50 at 6 months, FDA alignment on single Phase 3, and $300M raise knocked out all three bear-case legs; binary catalyst risk substantially de-risked.
5. 2026-05-19 Watch UPDATE: Artiva (ARTV) - The CFO Walks. Ten Days After the Raise. CFO departing ten days after the $300M raise is a governance signal that warrants downgrading to Watch pending clarity on the CFO search.
6. 2026-06-08 Speculative buy speculative UPDATE: Artiva (ARTV) - RMAT Lands, EULAR Confirms, CFO Seat Still Empty RMAT designation and EULAR validation of 71% ACR50 data provide sufficient de-risking to re-upgrade despite CFO seat remaining open.
7. 2026-06-16 Speculative buy speculative UPDATE: Artiva (ARTV) - RA Capital Goes to 36.6% RA Capital buying 1.43M shares at $6.77–$9.00 post-CFO-exit, reaching 36.6%, signals the largest specialist on the cap table treats the governance flag as noise.
8. 2026-07-24 Speculative buy speculative UPDATE: Artiva (ARTV) - Kolchinsky Keeps Buying. Now at 37.9%. RA Capital continued buying into strength up to $9.96, reaching 37.9%, reinforcing the specialist conviction signal while CFO seat remains open.
9. 2026-08-07 Speculative buy speculative UPDATE: Artiva (ARTV) - The CFO Clock Ran Out. Nobody Blinked. $349.4M confirmed through 2029 past Phase 3 readout, mechanism peer-reviewed, and market/RA Capital both shrugging off open CFO seat; binary now purely biological.
10. 2026-10-28 Avoid UPDATE: Artiva (ARTV) - Both Halves of the Bet Broke AlloNK durability failed at longer follow-up, a patient died from fludarabine neurotoxicity, Phase 3 cancelled, 94% workforce cut; the thesis is dead and what remains is a cash shell.

• Long call · opened May 11, 2026 at $10.60 · closed May 20, 2026 (downgraded to WATCH from long) at $7.84 · -26.0% vs XBI -2.4%
• Long call · opened Jun 9, 2026 at $7.27 · closed Oct 28, 2026 (flipped bearish (avoid)) at $4.28 · -41.2% vs XBI +19.9%
• Avoid call · opened Oct 28, 2026 at $4.28 · -2.9% vs XBI -3.4% (Nov 6, 2026)

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (2 quotes from 2 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

• 2026-08-06 10-Q in filings ↓

  • “We are initiating the registrational trial in the second half of 2026 and expect to report primary efficacy data in the second half of 2028, with a potential BLA submission in 2029.”

    matched to AlloNK + rituximab (Phase 2a basket update, ACR Convergence 2026) · interim data · read as second half of 2026
• 2026-08-06 10-Q in filings ↓

  • “The guidance is effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027.”

    matched to Company · Webcast with Paul Emery; listen for CFO-search language · read as December 15, 2026

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (36)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 8, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

• Oct 27, 2026ReleaseArtiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK®→ BD updateSummary on the 8-KBD extracted 1 program update from this document → ARTV pipeline
• Oct 27, 20268-KCurrent report: results of operations, exit / restructuring costs · EX-99.1→ BD updateArtiva killed AlloNK this morning — durability failed, two patients died, 94% of staff are being let go, and the Phase 3 is cancelled. The bear case I named in December just got confirmed in the most brutal way possible, and the only thing left standing is $319M in cash and a strategic alternatives process.BD extracted 1 program update from this document → ARTV pipeline
• Oct 2, 2026ReleaseArtiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026BD extracted 1 program update from this document → ARTV pipeline
• Oct 1, 2026ReleaseArtiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren’s Disease (ISSjD 2026)BD extracted 1 program update from this document → ARTV pipeline
• Sep 23, 2026ReleaseArtiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren’s DiseaseBD extracted 1 program update from this document → ARTV pipeline
• Sep 17, 2026ReleaseArtiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
• Sep 11, 20268-KCurrent report: officer / director change, shareholder vote
• Sep 8, 2026ReleaseArtiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026Artiva just set the clock on its most consequential near-term data release: ≥20 refractory RA patients with ≥6 months of follow-up — nearly 3x the n=7 that drove the 76% re-rating in May — arriving in H2 2026, alongside Phase 3 enrollment initiation. The 71% ACR50 is about to get its first real stress test.BD extracted 1 program update from this document → ARTV pipeline
• Sep 2, 2026ReleaseArtiva Biotherapeutics to Participate in Upcoming Investor Conferences in September
• Aug 6, 2026S-3Shelf registration
• Aug 6, 2026ReleaseArtiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business HighlightsBD extracted 1 program update from this document → ARTV pipeline
• Aug 6, 20268-KCurrent report: results of operations · EX-99.1
• Aug 6, 202610-QQuarterly report
• Aug 3, 2026DEF 14AProxy statement
• Jul 23, 2026SCHEDULE 13D/A13D amendment
• Jul 22, 20268-KCurrent report: other events
• Jun 23, 2026ReleaseArtiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
• Jun 15, 2026SCHEDULE 13D/A13D amendment
• Jun 8, 2026ReleaseArtiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast TodayBD extracted 1 program update from this document → ARTV pipeline
• May 28, 2026SCHEDULE 13D/A13D amendment
• May 28, 2026ReleaseArtiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
• May 19, 2026ReleaseArtiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development
• May 19, 2026ReleaseArtiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cel
• May 19, 20268-KCurrent report: officer / director change
• May 13, 2026SCHEDULE 13D/A13D amendment
• May 8, 2026ReleaseArtiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
• May 8, 2026ReleaseArtiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
• May 8, 2026ReleaseArtiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026
• May 8, 2026FWPFree writing prospectus (offering terms)
• May 8, 20268-KCurrent report: other events
• May 8, 20268-KCurrent report: results of operations, Reg FD disclosure, other events · EX-99.1
• May 8, 2026424B5Prospectus supplement (offering)
• May 8, 202610-QQuarterly report
• Apr 30, 202610-K/AAnnual report (amended)
• Mar 10, 20268-KCurrent report: results of operations · EX-99.1
• Mar 10, 202610-KAnnual report